The ailing dialysis subsidiary FMC causes big problems.
(Photo: Fresenius)
Frankfurt The stock market showed how great the expectations are for the new Fresenius boss Michael Sen this week: the health care group’s shares have increased by ten percent since Monday. One reason was that the quarterly results weren’t so bad. But this is driven more by the fact that the CEO wants to intervene deeply in the structures of the Dax group.
The conversion will be the number one topic at the Fresenius Annual General Meeting next Wednesday. Sen wants to make the company more efficient and profitable with a new structure: essentially with the pharmaceutical subsidiary Kabi and the hospital operator Helios. The dialysis subsidiary Fresenius Medical Care (FMC) is to be deconsolidated and no longer appear on the balance sheet.
Read on now
Get access to this and every other article in the
Web and in our app free of charge for 4 weeks.
Further
Read on now
Get access to this and every other article in the
web and in our app.
Further